Gilead Sciences, Inc. (GILD) Monday announced that the European Medicines Agency has validated its applications for accelerated review of lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor for HIV prevention.
The EU-M4all application aims to fast-track lenacapavir's approval in low- and lower-middle-income countries. Phase 3 trials showed lenacapavir reduced HIV risk by 100 percent in cisgender women and 96 percent in cisgender men and gender-diverse people.
This follows the U.S. FDA's recent acceptance of lenacapavir for priority review, underscoring global interest in its potential to advance HIV prevention efforts.
GILD is currently trading at $111.43 up 1.35 percent or $1.48 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.